143 related articles for article (PubMed ID: 22391053)
1. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk.
Efstathiou JA; Paly JJ; Lu HM; Athar BS; Moteabbed M; Niemierko A; Adams JA; Bekelman JE; Shipley WU; Zietman AL; Paganetti H
Radiother Oncol; 2012 Apr; 103(1):12-7. PubMed ID: 22391053
[TBL] [Abstract][Full Text] [Related]
2. Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma.
Simone CB; Kramer K; O'Meara WP; Bekelman JE; Belard A; McDonough J; O'Connell J
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):242-9. PubMed ID: 21236595
[TBL] [Abstract][Full Text] [Related]
3. Projected second tumor risk and dose to neurocognitive structures after proton versus photon radiotherapy for benign meningioma.
Arvold ND; Niemierko A; Broussard GP; Adams J; Fullerton B; Loeffler JS; Shih HA
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e495-500. PubMed ID: 22285662
[TBL] [Abstract][Full Text] [Related]
4. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma.
Zwahlen DR; Martin JM; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):853-8. PubMed ID: 18164856
[TBL] [Abstract][Full Text] [Related]
5. Improving the therapeutic ratio by using proton therapy in patients with stage I or II seminoma.
Hoppe BS; Mamalui-Hunter M; Mendenhall NP; Li Z; Indelicato DJ
Am J Clin Oncol; 2013 Feb; 36(1):31-7. PubMed ID: 22134517
[TBL] [Abstract][Full Text] [Related]
6. Predicted Rate of Secondary Malignancies Following Adjuvant Proton Versus Photon Radiation Therapy for Thymoma.
Vogel J; Lin L; Litzky LA; Berman AT; Simone CB
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):427-433. PubMed ID: 28871993
[TBL] [Abstract][Full Text] [Related]
7. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas.
Weber DC; Trofimov AV; Delaney TF; Bortfeld T
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1596-606. PubMed ID: 15050341
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
9. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer.
Nichols RC; Huh SN; Prado KL; Yi BY; Sharma NK; Ho MW; Hoppe BS; Mendenhall NP; Li Z; Regine WF
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):158-63. PubMed ID: 22245197
[TBL] [Abstract][Full Text] [Related]
10. Second primary cancer in irradiated stage I testicular seminoma.
Stein ME; Steiner M; Lachter J; Kessel I; Moskovitz B; Kuten A
Strahlenther Onkol; 1993 Nov; 169(11):672-7. PubMed ID: 8248844
[TBL] [Abstract][Full Text] [Related]
11. Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma.
Lewinshtein D; Gulati R; Nelson PS; Porter CR
BJU Int; 2012 Mar; 109(5):706-12. PubMed ID: 21883828
[TBL] [Abstract][Full Text] [Related]
12. [Treatment options in early-stage testicular seminoma. Review of the literature with initial results of a prospective multicenter study on radiotherapy of clinical-stage I, IIA and IIB seminomas].
Schmidberger H; Bamberg M
Strahlenther Onkol; 1995 Mar; 171(3):125-39. PubMed ID: 7709330
[TBL] [Abstract][Full Text] [Related]
13. Results of radiotherapy for 230 patients with stage I-II seminomas.
Hültenschmidt B; Budach V; Genters K; Sack H
Strahlenther Onkol; 1996 Apr; 172(4):186-92. PubMed ID: 8623080
[TBL] [Abstract][Full Text] [Related]
14. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).
Chan R
J Clin Oncol; 2005 Sep; 23(27):6806; author reply 6806-7. PubMed ID: 16170196
[No Abstract] [Full Text] [Related]
16. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans.
Wang X; Krishnan S; Zhang X; Dong L; Briere T; Crane CH; Martel M; Gillin M; Mohan R; Beddar S
Med Dosim; 2008; 33(4):259-67. PubMed ID: 18973852
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic follow-up in testicular seminoma patients exposed to adjuvant radiotherapy.
Gamulin M; Kopjar N; Grgić M; Ramić S; Viculin T; Petković M; Garaj-Vrhovac V
Coll Antropol; 2010 Jun; 34(2):455-65. PubMed ID: 20698117
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy treatment planning for testicular seminoma.
Wilder RB; Buyyounouski MK; Efstathiou JA; Beard CJ
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e445-52. PubMed ID: 22436787
[TBL] [Abstract][Full Text] [Related]
19. Plan robustness in proton beam therapy of a childhood brain tumour.
Lassen-Ramshad Y; Vestergaard A; Muren LP; Høyer M; Petersen JB
Acta Oncol; 2011 Aug; 50(6):791-6. PubMed ID: 21767176
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328).
Jones WG; Fossa SD; Mead GM; Roberts JT; Sokal M; Horwich A; Stenning SP
J Clin Oncol; 2005 Feb; 23(6):1200-8. PubMed ID: 15718317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
